Employees: 2,645
Size R&G PharmaStudies (301333.SZ) is a China Health Care company (Biotechnology) with a market value of $722M, the 2831st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥51.05 on 18 Nov 2026.
Performance Over six months the shares fell 11.2%, against -22.6% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue grew 21.3% over the last twelve months (peer median +7.1%); the operating margin is 11.3% (peer median -99.9%).
Valuation It trades at 37.9× forward earnings against a peer median of 19.4× (most expensive of 4).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 16.0 points above its cost of capital (9.3% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥957M | CN¥847M | CN¥741M | CN¥718M | CN¥635M |
| Revenue growth | — | +14% | +3% | +13% | — |
| Gross profit | CN¥317M | CN¥289M | CN¥270M | CN¥280M | CN¥229M |
| EBITDA | n/a | CN¥160M | CN¥157M | CN¥168M | CN¥141M |
| Net income | CN¥117M | CN¥137M | CN¥140M | CN¥163M | CN¥113M |
| Free cash flow | CN¥107M | CN¥116M | CN¥158M | CN¥198M | CN¥119M |
| Capital expenditure | CN¥16.0M | CN¥19.3M | CN¥20.0M | CN¥19.9M | CN¥20.8M |
| Total debt | CN¥50.1M | CN¥17.9M | CN¥71.9M | CN¥8.86M | CN¥15.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301333.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.8% | -7.2% | 10th highest of 21 |
| 6-month return | -11.2% | -22.6% | 7th highest of 19 |
| Distance from 52-week high | -44.4% | -47.7% | 7th highest of 21 |
| Revenue growth (TTM) | +21.3% | +7.1% | 6th highest of 15 |
| Operating margin | 11.3% | -99.9% | 3rd highest of 17 |
| Forward P/E | 37.9× | 19.4× | most expensive of 4 |
| Growth the price implies (Req g, 7 yrs) | 17.3% | 24.1% | 3rd least demanding of 5 |
| Growth delivered (Del g) | +11.8% | +8.5% | 3rd highest of 5 |
| Hurdle (Req g minus delivered) | +5.5 pp | +12.1 pp | 3rd least demanding of 5 |
| ROIC minus cost of capital | +16.0 pp | -15.9 pp | 2nd highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 37.9× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | n/a | -13.5% | -10.9% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | n/a | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | n/a | 44.8% | +14.7% |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | n/a | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | n/a | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 19.4× | 7.8% | +2.4% |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 24.0× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | n/a | 40.3% | +21.5% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 17.4× | n/a | n/a |